Research advances in acute pancreatitis scoring system

Xiuping LUO; Jie WANG; Qing WU; Mengbin QIN; Shiquan LIU; Jiean HUANG

doi:10.3969/j.issn.1001-5256.2022.09.046

Volume 38 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(9): 2188-2192

PDF( 1967 KB)

Research advances in acute pancreatitis scoring system

DOI: 10.3969/j.issn.1001-5256.2022.09.046

Department of Gastroenterology, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530007, China

Research funding:

Scientific Research Project of Guangxi Health Commission (Z20210625);

Science Foundation Project of the Second Affiliated Hospital of Guangxi Medical University (EFYKY2020007)

More Information

Corresponding author: HUANG Jiean, hjagxmu@163.com(ORCID: 0000-0003-0431-1888)
Received Date: 2022-02-10
Accepted Date: 2022-03-15
Published Date: 2022-09-20

Abstract

Abstract

Acute pancreatitis (AP) is a severe disease with an increasing incidence rate in clinical practice. Although most patients have mild pancreatitis, the fatality rate of severe pancreatitis remains at a relatively high level, and therefore, early-stage, simple, and accurate clinical scoring systems are urgently needed to determine the severity of AP, so as to facilitate effective disease management and symptomatic treatment and reduce the fatality rate of patients. At present, a large number of studies have demonstrated that the scoring systems such as Ranson score, APACHE Ⅱ score, BISAP score, CTSI score, and some serological markers have been used to evaluate the severity and prognosis of AP, but all of them have certain limitations. This article reviews the research advances in the existing scoring systems, single serological markers, and related modified scoring systems in recent years. Through a literature review, it is concluded that there is no a single scoring system or a single indicator that can cover the whole process of AP diagnosis and treatment and accurately judge the severity of AP, and therefore, it is necessary to develop a new scoring system or combine various indicators for comprehensive evaluation.
- Pancreatitis,
- Score,
- Prognosis

FullText(HTML)

References(39)

References

[1]	PETROV MS, YADAV D. Global epidemiology and holistic prevention of pancreatitis[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(3): 175-184. DOI: 10.1038/s41575-018-0087-5.
[2]	VEGE SS, GARDNER TB, CHARI ST, et al. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include "moderately severe acute pancreatitis"[J]. Am J Gastroenterol, 2009, 104(3): 710-715. DOI: 10.1038/ajg.2008.77.
[3]	GUDA NM, TRIKUDANATHAN G, FREEMAN ML. Idiopathic recurrent acute pancreatitis[J]. Lancet Gastroenterol Hepatol, 2018, 3(10): 720-728. DOI: 10.1016/S2468-1253(18)30211-5.
[4]	Pancreas Study Group, Chinese Society of Gastroenterology, Chinese Medical Association; Editorial Board of Chinese Journal of Pancreatology; Editorial Board of Chinese Journal of Digestion. Chinese guidelines for the management of acute pancreatitis (Shenyang, 2019) [J]. J Clin Hepatol, 2019, 35(12): 2706-2711. DOI: 10.3969/j.issn.1001-5256.2019.12.013. 中华医学会消化病学分会胰腺疾病学组, 《中华胰腺病杂志》编委会, 《中华消化杂志》编委会. 中国急性胰腺炎诊治指南(2019年, 沈阳)[J]. 临床肝胆病杂志, 2019, 35(12): 2706-2711. DOI: 10.3969/j.issn.1001-5256.2019.12.013.
[5]	LIU SZ, YAO JR, MO SJ, et al. Research progress of nutrition support for severe acute pancreatitis[J/CD]. Chin J Hepat Surg(Electronic Edition), 2021, 10(5): 533-535. DOI: 10.3969/j.issn.1006-2084.2017.20.021. 刘世洲, 姚佳柔, 莫绍剑, 等. 重症急性胰腺炎营养支持研究进展[J/CD]. 中华肝脏外科手术学电子杂志, 2021, 10(5): 533-535. DOI: 10.3969/j.issn.1006-2084.2017.20.021.
[6]	SUN B, LI GQ. Surgical intervention strategies for local complications of severe acute pancreatitis[J]. Chin J Dig Surg, 2020, 4(4): 379-383. DOI: 10.3760/cma.j.cn115610-20200121-00040. 孙备, 李冠群. 重症急性胰腺炎局部并发症外科干预策略[J]. 中华消化外科杂志, 2020, 4(4): 379-383. DOI: 10.3760/cma.j.cn115610-20200121-00040.
[7]	RANSON JH, RIFKIND KM, ROSES DF, et al. Prognostic signs and the role of operative management in acute pancreatitis[J]. Surg Gynecol Obstet, 1974, 139(1): 69-81.
[8]	RANSON JH, PASTERNACK BS. Statistical methods for quantifying the severity of clinical acute pancreatitis[J]. J Surg Res, 1977, 22(2): 79-91. DOI: 10.1016/0022-4804(77)90045-2.
[9]	ONG Y, SHELAT VG. Ranson score to stratify severity in acute pancreatitis remains valid-old is gold[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(8): 865-877. DOI: 10.1080/17474124.2021.1924058.
[10]	YANG CJ, CHEN J, PHILLIPS AR, et al. Predictors of severe and critical acute pancreatitis: a systematic review[J]. Dig Liver Dis, 2014, 46(5): 446-451. DOI: 10.1016/j.dld.2014.01.158.
[11]	MIKÓ A, VIGHÉ, MÁTRAI P, et al. Computed tomography severity index vs. other indices in the prediction of severity and mortality in acute pancreatitis: a predictive accuracy meta-analysis[J]. Front Physiol, 2019, 10: 1002. DOI: 10.3389/fphys.2019.01002.
[12]	GAO W, YANG HX, MA CE. The value of BISAP score for predicting mortality and severity in acute pancreatitis: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(6): e0130412. DOI: 10.1371/journal.pone.0130412.
[13]	WU BU, JOHANNES RS, SUN X, et al. The early prediction of mortality in acute pancreatitis: a large population-based study[J]. Gut, 2008, 57(12): 1698-1703. DOI: 10.1136/gut.2008.152702.
[14]	TANG HY, LIU S, HU CJ, et al. Value of modified objective Bedside Index for Severity in Acute Pancreatitis score in predicting the severity and prognosis of acute pancreatitis[J]. J Clin Hepatol, 2021, 37(6): 1386-1391. DOI: 10.3969/j.issn.1001-5256.2021.06.032. 唐豪佑, 刘胜, 胡程俊, 等. 改良客观性BISAP评分对急性胰腺炎严重程度及预后的预测价值[J]. 临床肝胆病杂志, 2021, 37(6): 1386-1391. DOI: 10.3969/j.issn.1001-5256.2021.06.032.
[15]	ZANWAR S, MOHAN AT, PARAMSIVAN P, et al. A novel "BISSHOAP" score for predicting severe and moderately severe acute pancreatitis in emergency room[J]. Gastroenterol Hepatol Endosc Pract, 2021, 1: 111-115. DOI: 10.4103/ghep.ghep-40-20.
[16]	KNAUS WA, DRAPER EA, WAGNER DP, et al. APACHE Ⅱ: a severity of disease classification system[J]. Crit Care Med, 1985, 13(10): 818-829. DOI: 10.1097/00003246-198510000-00009
[17]	GVRLEYIK G, ZAHIDULLAHOǦLU CIRPICI O, AKTEKIN A, et al. The value of Ranson and APACHE Ⅱ scoring systems, and serum levels of interleukin-6 and C-reactive protein in the early diagnosis of the severity of acute pancreatitis[J]. Ulus Travma Acil Cerrahi Derg, 2004, 10(2): 83-88. http://www.ncbi.nlm.nih.gov/pubmed/15103565
[18]	CHATZICOSTAS C, ROUSSOMOUSTAKAKI M, VLACHONIKOLIS IG, et al. Comparison of Ranson, APACHE Ⅱ and APACHE Ⅲ scoring systems in acute pancreatitis[J]. Pancreas, 2002, 25(4): 331-335. DOI: 10.1097/00006676-200211000-00002.
[19]	ALBERTI P, PANDO E, MATA R, et al. Evaluation of the modified computed tomography severity index (MCTSI) and computed tomography severity index (CTSI) in predicting severity and clinical outcomes in acute pancreatitis[J]. J Dig Dis, 2021, 22(1): 41-48. DOI: 10.1111/1751-2980.12961.
[20]	BAI L, WANG HY, XU WL, et al. Correlation between PTX-3, SIL-2R and APACHE Ⅱ score in patients with severe acute pancreatitis[J]. Chin J Public Health Eng, 2021, 20(4): 639-641. DOI: 10.19937/j.issn.1671-4199.2021.04.040. 白翎, 王宏宇, 许卫利, 等. PTX-3、SIL-2R血清水平变化与重症急性胰腺炎患者APACHEⅡ评分的相关性[J]. 中国卫生工程学, 2021, 20(4): 639-641. DOI: 10.19937/j.issn.1671-4199.2021.04.040.
[21]	MORTELE KJ, WIESNER W, INTRIERE L, et al. A modified CT severity index for evaluating acute pancreatitis: improved correlation with patient outcome[J]. AJR Am J Roentgenol, 2004, 183(5): 1261-1265. DOI: 10.2214/ajr.183.5.1831261.
[22]	LANKISCH PG, APTE M, BANKS PA. Acute pancreatitis[J]. Lancet, 2015, 386(9988): 85-96. DOI: 10.1016/S0140-6736(14)60649-8.
[23]	MACHIN SJ, BRIGGS C. Mean platelet volume: a quick, easy determinant of thrombotic risk?[J]. J Thromb Haemost, 2010, 8(1): 146-147. DOI: 10.1111/j.1538-7836.2009.03673.x.
[24]	COBAN E, AFACAN B. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment[J]. Platelets, 2008, 19(2): 111-114. DOI: 10.1080/09537100701230444.
[25]	GASPARYAN AY, AYVAZYAN L, MIKHAILIDIS DP, et al. Mean platelet volume: a link between thrombosis and inflammation?[J]. Curr Pharm Des, 2011, 17(1): 47-58. DOI: 10.2174/138161211795049804.
[26]	KAUSHANSKY K. The molecular mechanisms that control thrombopoiesis[J]. J Clin Invest, 2005, 115(12): 3339-3347. DOI: 10.1172/JCI26674.
[27]	CHU SG, BECKER RC, BERGER PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis[J]. J Thromb Haemost, 2010, 8(1): 148-156. DOI: 10.1111/j.1538-7836.2009.03584.x.
[28]	AKBAL E, DEMIRCI S, KOÇAK E, et al. Alterations of platelet function and coagulation parameters during acute pancreatitis[J]. Blood Coagul Fibrinolysis, 2013, 24(3): 243-246. DOI: 10.1097/MBC.0b013e32835aef51.
[29]	JIN L, ZHOU SP, CAO ZJ, et al. Correlation of platelet related parameters in predicting severity of acute pancreatitis [J]. J Clin Emerg, 2021, 20(2): 111-116. DOI: 10.13201/j.issn.1009-5918.2021.02.006. 金磊, 周淑萍, 曹子君, 等. 血小板相关参数在急性胰腺炎病情严重程度预测中的相关性研究[J]. 临床急诊杂志, 2021, 20(2): 111-116. DOI: 10.13201/j.issn.1009-5918.2021.02.006.
[30]	FU Y, ZHANG Q, LI MY, et al. Correlation analysis between platelet-related parameters and inflammatory indicators in patients with acute pancreatitis[J]. West China Med J, 2020, 35(8): 943-947. DOI: 10.7507/1002-0179.202006249. 付阳, 张琦, 李梦雨, 等. 急性胰腺炎患者血小板相关参数与炎性指标的相关性研究[J]. 华西医学, 2020, 35(8): 943-947. DOI: 10.7507/1002-0179.202006249.
[31]	HU QM, NIU CY. Predictive value of combined measurement of D-dimer, fibrinogen, and peripheral blood leukocyte count for severity of acute pancreatitis[J]. J Clin Hepatol, 2017, 33(8): 1522 -1526. DOI: 10.3969/j.issn.1001-5256.2017.08.023. 虎青梅, 牛春燕. D-二聚体、纤维蛋白原、外周血白细胞计数联合检测对急性胰腺炎严重程度的预测价值[J]. 临床肝胆病杂志, 2017, 33(8): 1522-1526. DOI: 10.3969/j.issn.1001-5256.2017.08.023.
[32]	YU SS, JIN K, FU YY, et al. Predictive value of D-dimer combination-related indicators in the severity of acute pancreatitis[J]. J Clin Emerg, 2019, 20(12): 925-930. DOI: 10.13201/j.issn.1009-5918.2019.12.003. 余姗姗, 金魁, 付阳阳, 等. D-二聚体联合相关指标在急性胰腺炎严重程度预测中的价值研究[J]. 临床急诊杂志, 2019, 20(12): 925-930. DOI: 10.13201/j.issn.1009-5918.2019.12.003.
[33]	SINGH AK, DAWRA S, RANA S, et al. Can serum resistin predict severity of acute pancreatitis?[J]. Biomarkers, 2021, 26(1): 31-37. DOI: 10.1080/1354750X.2020.1841295.
[34]	AL-BAHRANI AZ, AMMORI BJ. Clinical laboratory assessment of acute pancreatitis[J]. Clin Chim Acta, 2005, 362(1-2): 26-48. DOI: 10.1016/j.cccn.2005.06.008.
[35]	ZHANG FX, LI ZL, ZHANG ZD, et al. Prognostic value of red blood cell distribution width for severe acute pancreatitis[J]. World J Gastroenterol, 2019, 25(32): 4739-4748. DOI: 10.3748/wjg.v25.i32.4739.
[36]	LEI JJ, ZHOU L, LIU Q, et al. Can mean platelet volume play a role in evaluating the severity of acute pancreatitis?[J]. World J Gastroenterol, 2017, 23(13): 2404-2413. DOI: 10.3748/wjg.v23.i13.2404.
[37]	WANG F, MENG Z, LI S, et al. Platelet distribution width levels can be a predictor in the diagnosis of persistent organ failure in acute pancreatitis[J]. Gastroenterol Res Pract, 2017, 2017: 8374215. DOI: 10.1155/2017/8374215.
[38]	ZHOU H, MEI X, HE X, et al. Severity stratification and prognostic prediction of patients with acute pancreatitis at early phase: A retrospective study[J]. Medicine (Baltimore), 2019, 98(16): e15275. DOI: 10.1097/MD.0000000000015275.
[39]	KIBAR YI, ALBAYRAK F, ARABUL M, et al. Resistin: New serum marker for predicting severity of acute pancreatitis[J]. J Int Med Res, 2016, 44(2): 328-337. DOI: 10.1177/0300060515605428.

Relative Articles

[1]	Haifeng LIU, Simin ZHOU, Jiwen LI, Jiangpeng LIU, Bangmao WANG, Lu ZHOU. Effect of depression on response to ursodeoxycholic acid and the occurrence of liver cirrhosis in patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2817-2823. doi: 10.3969/j.issn.1001-5256.2023.12.011
[2]	Zhang JingQiao, Li MiaoMiao, Qi XingShun, Ceng QingLei, Jia JiDong. An excerpt of update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Journal of Clinical Hepatology, 2018, 34(12): 2563-2567. doi: 10.3969/j.issn.1001-5256.2018.12.011
[3]	Zhang JingQiao, Li MiaoMiao, Qi XingShun, Ceng QingLei. An excerpt of update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Journal of Clinical Hepatology, 2018, 34(4): 737-742. doi: 10.3969/j.issn.1001-5256.2018.04.009
[4]	Gao ShengLi, Zhao Gang, Xu MiQin, Shen Yan, Yu Jing, Ye Yang, He LiHua, Jin WenJuan, Sun GuiYing, Niu ZhiLin. Efficacy and safety of interferon-α given additionally or sequentially after long-term entecavir therapy in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(2): 268-271. doi: 10.3969/j.issn.1001-5256.2018.02.010
[5]	Wan MoBin. Individualized treatment with pegylated interferon-α for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(5): 930-933. doi: 10.3969/j.issn.1001-5256.2018.05.004
[6]	Ma XiQuan, Xiong WuJun, Liu Lu, Wang YiFei, Cheng Jie, Zhang ZhengXia, Zhao Hui, Qu LiHong. Current status of anxiety and depression among hepatitis B patients in Shanghai, China and related influencing factors[J]. Journal of Clinical Hepatology, 2018, 34(8): 1664-1668. doi: 10.3969/j.issn.1001-5256.2018.08.014
[7]	Tao JunXiu, Li XiaoDong, Cao Ting, Xiao MingZhong, Wu HuiKun, Wu Deng, Ren Meng, Wang Ting, Bai LiYing. A study of compliance in patients with HBeAg-negative chronic hepatitis B receiving entecavir treatment[J]. Journal of Clinical Hepatology, 2017, 33(8): 1558-1560. doi: 10.3969/j.issn.1001-5256.2017.08.030
[8]	Sun YaMeng, You Hong. Advances in staging and treatment of hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1036-1039. doi: 10.3969/j.issn.1001-5256.2016.06.003
[9]	Ning Ling, Sun Jian, Chen Nan, Hou JinLin. Renal safety in chronic hepatitis B patients treated with nucleos(t) ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(5): 981-985. doi: 10.3969/j.issn.1001-5256.2016.05.042
[10]	Han BenLi. Clinical efficacy of entecavir in HBeAg-negative chronic hepatitis B with compensated cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1525-1528. doi: 10.3969/j.issn.1001-5256.2016.08.018
[11]	Xie YongCai, Hu GuoXin, Peng YanZhong, Zheng Jie, Li YinPing. Clinical effect of Dahuang Zhechong capsules combined with entecavir in treatment of chronic hepatitis B patients with liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1502-1507. doi: 10.3969/j.issn.1001-5256.2016.08.014
[12]	Hu XiaoYun, Sun Jian, Peng Jie. New considerations in antiviral therapy for special populations with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(11): 2054-2057. doi: 10.3969/j.issn.1001-5256.2016.11.007
[13]	Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on antiviral therapy for chronic hepatitis B with renal injury or high risk of renal injury[J]. Journal of Clinical Hepatology, 2016, 32(12): 2242-2247. doi: 10.3969/j.issn.1001-5256.2016.12.004
[14]	Gao YanHang, Liu PeiYan, Gao PuJun. Advances in research and development of new drugs for antiviral therapy for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(11): 2043-2049. doi: 10.3969/j.issn.1001-5256.2016.11.005
[15]	Zhu DongLiang, Li DaoBo, Zhao ManZhi, Ma Ke, Song JianXin, Xu Dong. Clinical effect of entecavir in treatment of patients with chronic hepatitis B complicated by tuberculosis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2084-2087. doi: 10.3969/j.issn.1001-5256.2016.11.014
[16]	Wang QingHai, Luo KaiZhong, Tian Yi. Effect and safety of bilirubin serum adsorption in treatment of patients with chronic severe hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1296-1299. doi: 10.3969/j.issn.1001-5256.2016.07.016
[17]	Yang XiaoYan, Sun ZhangYu, Yuan Xiang, Liang YaLin. Clinical analysis of hypophosphatemia induced by adefovir dipivoxil in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(12): 2047-2050. doi: 10.3969/j.issn.1001-5256.2015.12.014
[18]	Zhu ShiShu, Zhang HongFei. Antiviral therapy of chronic hepatitis B in children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1211-1214. doi: 10.3969/j.issn.1001-5256.2015.08.007
[19]	Yan Jie, Xie Wen. Expert consenus on antiviral therapy for special patients with chronic hepatitis B: an update in 2014[J]. Journal of Clinical Hepatology, 2014, 30(7): 580-587. doi: 10.3969/j.issn.1001-5256.2014.07.002
[20]	Liao YunFan, Jia-Horng Kao, Teerha Piratvisuth, et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2012 update[J]. Journal of Clinical Hepatology, 2012, 28(8): 641-661.

Supplements(0)

Cited By

Cited by

Periodical cited type(20)

1.	王勇，倪雷，闫波，司运飞. 规则性肝段切除在肝内胆管结石患者中的应用. 贵州医药. 2021(07): 1154-1155 .
2.	蒋增强，石耀. 解剖性肝切除术治疗60岁以下肝胆管结石患者的临床效果观察. 临床研究. 2020(02): 54-55 .
3.	朱景波. 腹腔镜胆道探查取石术治疗肝内外胆管结石的效果观察. 临床医学. 2020(05): 75-77 .
4.	黄春雷，廖朝兴. 超声引导下PTCD治疗治疗恶性梗阻性黄疸的临床疗效及安全性分析. 实用心脑肺血管病杂志. 2020(S1): 83-85 .
5.	侯勇，李克志，王永平，张宏. 解剖性肝切除术与非规则性肝切除术治疗肝内胆管结石效果分析. 中国继续医学教育. 2019(06): 92-94 .
6.	王金宝，谭庆娟，王维山，刘成彪，孙启栋. 腹腔镜肝段切除术治疗左肝胆管结石的随机对照研究. 腹腔镜外科杂志. 2019(05): 356-359 .
7.	倪颖，贺登秀，徐滔. 自拟中药方结合腹腔镜联合胆道镜手术治疗肝内外胆管结石疗效观察. 四川中医. 2019(07): 113-116 .
8.	郭威，张冲，李桂鲜，吴嘉兴，蒋建晖，姚红兵. 解剖性肝切除在严重肝外伤手术中的应用. 河北医科大学学报. 2019(09): 1034-1037 .
9.	辛大平，彭彬，黄明，黄纪伟. 精准肝切除与非规则性肝切除治疗肝内胆管结石效果比较. 郑州大学学报(医学版). 2019(05): 762-765 .
10.	白庆鹤. 精准肝切除术与非规则性肝切除术治疗肝内胆管结石临床效果对比. 临床合理用药杂志. 2019(34): 149-150 .
11.	吴忠寅，丁锐. 左肝蒂阻断左半肝切除术在肝内胆管结石中应用临床观察. 创伤与急危重病医学. 2018(04): 235-236 .
12.	许长涛，郑方，王瑞官，李为民. 胆管结石性黄疸患者围术期内调节性T细胞免疫功能变化临床研究. 临床军医杂志. 2018(08): 865-868 .
13.	王新团，李山林，耿智敏. 腹腔镜与开腹肝切除术治疗区域型肝胆管结石病的倾向性评分匹配研究. 临床肝胆病杂志. 2018(03): 531-534 . 本站查看
14.	皇甫行勋. 腹腔镜解剖性肝左外叶切除术治疗肝内胆管结石. 牡丹江医学院学报. 2018(04): 64-65+90 .
15.	辛莘，郐大余，徐宝宏. ERCP、十二指肠乳头小切开联合乳头括约肌气囊扩张术在肝外胆管结石治疗中的临床应用. 中国医刊. 2018(04): 388-389 .
16.	唐梅，巫强，龙洪航，熊雪娇. 解剖性肝切除术与非规则性肝切除术治疗肝内胆管结石效果分析. 北华大学学报(自然科学版). 2018(03): 367-370 .
17.	周建平，许平平，贺小武，谢鹏，王立. CT诊断与外科治疗在严重闭合性肝外伤救治中应用价值研究. 临床军医杂志. 2018(10): 1233-1234 .
18.	周龙飞，朱鸿超，刘洪亮，黄明文. 腹腔镜肝切除术在肝胆管结石治疗中的应用. 中华肝脏外科手术学电子杂志. 2018(05): 371-374 .
19.	李留峥，徐雷升，俸家伟，王志萍，高学昌，龚国茶，敖强，于杰. 解剖性肝切除术治疗复杂肝内胆管结石体会. 腹部外科. 2017(06): 456-459+463 .
20.	李留峥，徐雷升，俸家伟，王志萍，高学昌，龚国茶，敖强，于杰. Glisson蒂横断式解剖性肝切除120例治疗体会. 肝胆胰外科杂志. 2017(05): 359-362+367 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (859) PDF downloads(77)

Research advances in acute pancreatitis scoring system

DOI: 10.3969/j.issn.1001-5256.2022.09.046